The effects of MYC on exosomes derived from cancer cells in the context of breast cancer

MYC amplification and overexpression in breast cancer occur 16% and 22%, respectively, and MYC has a linchpin role in breast carcinogenesis. Emerging evidence has started to shed light on central role of MYC in breast cancer progression. On the contrary, tumor‐derived exosomes and their cargo molecules are required for the modulation of the tumor environment and to promote carcinogenesis. Still, how MYC regulates tumor‐derived exosomes is still a matter of investigation in the context of breast cancer. Here, we investigated for the first time how MYC affects the biological functions of normal breast cells cocultured with exosomes derived from MYC‐expression manipulated breast cancer cells. Accordingly, exosomes were isolated from MCF‐7 and MDA‐MB‐231 cells that MYC expression was manipulated through siRNAs or lentiviral vectors by using exosome isolation reagent. Then, normal breast epithelial MCF‐10A cells were treated with breast cancer cell‐derived exosomes. The cellular activity of MCF‐10A was investigated by cell growth assay, wound healing assay, and transwell assay. Our results suggested that MCF‐10A cells treated with exosomes derived from MYC‐overexpressing breast cancer cells demonstrated higher proliferation and migration capability compared with nontreated cells. Likewise, MCF‐10A cells treated with exosomes derived from MYC‐silenced cancer cells did not show high proliferation and invasive capacity. Overall, MYC can drive the functions of exosomes secreted from breast cancer cells. This may allow exploring a new mechanism how tumor cells regulate cancer progression and modulate tumor environment. The present study clears the way for further researches as in vivo studies and multi‐omics that clarify exosomal content in an MYC‐dependent manner.

[1]  Delaney K Sullivan,et al.  MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes , 2022, Oncogene.

[2]  Ye Li,et al.  Targeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer , 2022, Experimental & Molecular Medicine.

[3]  Kathleen E. Houlahan,et al.  Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer , 2022, Nature Communications.

[4]  O. Tokgün,et al.  Myc manipulates the miRNA content and biologic functions of small cell lung cancer cell-derived small extracellular vesicles , 2022, Molecular Biology Reports.

[5]  Xinyu Wang,et al.  Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression , 2022, Nature communications.

[6]  C. Quintavalle,et al.  Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer , 2022, Molecular therapy. Nucleic acids.

[7]  J. Arribas,et al.  MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding , 2022, Cancer research communications.

[8]  P. Sepúlveda,et al.  Non-classical Notch signaling by MDA-MB-231 breast cancer cell-derived small extracellular vesicles promotes malignancy in poorly invasive MCF-7 cells , 2022, Cancer Gene Therapy.

[9]  Yongmei Yin,et al.  The Advancing Roles of Exosomes in Breast Cancer , 2021, Frontiers in Cell and Developmental Biology.

[10]  Chunyang Jiang,et al.  Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms , 2021, Molecular Cancer.

[11]  D. Felsher,et al.  The MYC oncogene — the grand orchestrator of cancer growth and immune evasion , 2021, Nature Reviews Clinical Oncology.

[12]  D. Andrews,et al.  MYC protein interactors in gene transcription and cancer , 2021, Nature Reviews Cancer.

[13]  D. Nomura,et al.  Oncogene-regulated release of extracellular vesicles. , 2021, Developmental cell.

[14]  Jun Zhu,et al.  Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer , 2021, Science Advances.

[15]  Masafumi Nakamura,et al.  Comprehensive molecular profiling broadens treatment options for breast cancer patients , 2020, Cancer medicine.

[16]  Erik Knutsen,et al.  Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies , 2020, International journal of molecular sciences.

[17]  M. Girvan,et al.  MYC amplifies gene expression through global changes in transcription factor dynamics. , 2020, Cell reports.

[18]  Bing Zhang,et al.  IKKβ Activation Promotes Amphisome Formation and Extracellular Vesicle Secretion in Tumor Cells. , 2020, Biochimica et biophysica acta. Molecular cell research.

[19]  Xi-sha Chen,et al.  PKM2–c-Myc–Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer , 2020, Frontiers in Pharmacology.

[20]  Y. Tao,et al.  Exosomes: key players in cancer and potential therapeutic strategy , 2020, Signal Transduction and Targeted Therapy.

[21]  O. Tokgun,et al.  llncRNAs as Potential Targets in Small Cell Lung Cancer: Myc Dependent Regulation. , 2020, Anti-cancer agents in medicinal chemistry.

[22]  L. Soucek,et al.  Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc , 2020, Cells.

[23]  M. Eilers,et al.  Target gene-independent functions of MYC oncoproteins , 2020, Nature Reviews Molecular Cell Biology.

[24]  Colin J. Daniel,et al.  Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity. , 2019, The Journal of clinical investigation.

[25]  Matthew A. Clarke,et al.  Heterogeneity of Myc expression in breast cancer exposes pharmacological vulnerabilities revealed through executable mechanistic modeling , 2019, Proceedings of the National Academy of Sciences.

[26]  O. Tokgun,et al.  MYC-driven regulation of long non-coding RNA profiles in breast cancer cells. , 2019, Gene.

[27]  J. Wesseling,et al.  Proteomic profiling of extracellular vesicles allows for human breast cancer subtyping , 2019, Communications Biology.

[28]  Christopher G. Adda,et al.  Exosomes from N-Myc amplified neuroblastoma cells induce migration and confer chemoresistance to non-N-Myc amplified cells: implications of intra-tumour heterogeneity , 2019, Journal of extracellular vesicles.

[29]  I. Huijbers,et al.  Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer , 2019, Nature Communications.

[30]  I. Cavalli,et al.  Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells , 2018, Breast Cancer Research and Treatment.

[31]  A. Esnakula,et al.  MYC amplification in subtypes of breast cancers in African American women , 2018, BMC Cancer.

[32]  G. Qing,et al.  Targeting oncogenic Myc as a strategy for cancer treatment , 2018, Signal Transduction and Targeted Therapy.

[33]  Keivan Majidzadeh-A,et al.  Exosomes in Cancer Liquid Biopsy: A Focus on Breast Cancer , 2017, Molecular therapy. Nucleic acids.

[34]  A. Rishi,et al.  Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells , 2017, PloS one.

[35]  A. Shajahan-Haq,et al.  MYC-Driven Pathways in Breast Cancer Subtypes , 2017, Biomolecules.

[36]  O. Olopade,et al.  c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells , 2011, BMC Cancer.

[37]  Hongxia Zhu,et al.  Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo , 2004, Breast Cancer Research.

[38]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.